Study of bone problems after stopping breast cancer medicines
Part of Cancer, Skin clinical trials.
This observational study looks at bone complications in post-menopausal women with breast cancer after stopping denosumab and an aromatase inhibitor. It may help doctors better understand who is at risk for bone weakening and fractures after these medicines are stopped.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of breast cancer
- You are post-menopausal, meaning your last menstrual period was at least 12 months before enrolling
- You took denosumab at least twice, and then stopped it
- You stopped an aromatase inhibitor (AI) either before denosumab was stopped or within 6 months after your last denosumab shot
- You are age 18 or older
- You did NOT have osteoporosis or a prior “insufficiency fracture” before starting denosumab, based on a DEXA scan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks bone health in breast cancer patients receiving hormone-blocking therapy (aromatase inhibitors, GnRH analogs, or tamoxifen). It aims to understand how these treatments affect bone mineral density.
This trial tests whether giving zoledronic acid (a bone-strengthening infusion) right after stopping denosumab can help prevent bone loss in women with post-menopausal osteoporosis. It may be a good option if you have finished at least 2 years of denosumab and your doctor says it's safe to stop.
This study compares two medicines (ibandronate and zoledronic acid) to see which one works better at keeping bones strong after stopping denosumab (Prolia). It's for postmenopausal women with mild to moderate bone thinning.
This study tests whether denosumab, a medication that strengthens bones, can also improve muscle strength and insulin sensitivity in postmenopausal women with type 2 diabetes who take metformin.
This study tests a new form of calcium (amorphous calcium carbonate) to see if it can improve bone density in postmenopausal women with osteoporosis. It may offer an alternative for women who cannot or choose not to take other osteoporosis medications.
This study from Bursa City Hospital looks at how age affects the response to common osteoporosis medicines (denosumab or bisphosphonates) using bone density scans (DXA). It aims to see if older adults respond differently to treatment.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.